
Biotech Breakthrough: How Viking Therapeutics Aims to Transform Metabolic Disease Treatment
Viking Therapeutics is focused on treating metabolic and endocrine diseases with innovative approaches. The flagship drug, VK2735, targets obesity and type 2 diabetes by engaging GLP-1 and GIP receptors, showing rapid weight loss in Phase 2 trials. VK2735 offers both injectable and